26.80
Alumis Inc Aktie (ALMS) Neueste Nachrichten
Alumis (NASDAQ:ALMS) Shares Up 7.2%Still a Buy? - MarketBeat
Alumis Highlights Phase III Psoriasis Wins, NDA Timing, and Lupus Catalyst at Guggenheim Summit - Yahoo Finance
Quarterly Risk: Is Alumis Inc in a consolidation phase2025 Price Action Summary & Growth Focused Entry Reports - baoquankhu1.vn
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter. - AOL.com
Stop Loss: Is Alumis Inc gaining market shareJuly 2025 WrapUp & Daily Profit Focused Screening - baoquankhu1.vn
Alumis (ALMS) Valuation Check After Strong Multi‑Month Share Price Momentum - Yahoo Finance
EPS Watch: Can Alumis Inc ride the EV waveWeekly Stock Analysis & Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Market Leaders: Will TWFG outperform the market in YEARTrade Analysis Report & High Win Rate Trade Alerts - baoquankhu1.vn
Alumis Ownership Shifts As Shelf Filing And Conferences Shape Outlook - Sahm
Alumis to Participate in Upcoming February Investor Conferences - The Manila Times
Alumis Inc. (NASDAQ:ALMS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Alumis and ACELYRIN announce merger in all-stock deal - MSN
Alumis (NASDAQ:ALMS) Stock Price Up 9.8%What's Next? - MarketBeat
Alumis Inc stock (ALMS) jumps again on Nasdaq — here’s what’s driving the move and what comes next - TechStock²
Why Alumis Inc. Stock Is Suddenly Powering Higher - TipRanks
Chardan highlights Alumis’s (ALMS) potential after envudeucitinib hits all phase 3 endpoints in psoriasis trials - MSN
Alumis Inc. (ALMS) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Top Small Cap Stocks To Watch NowJanuary 6th - MarketBeat
Chardan Highlights Alumis's (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Finviz
Chardan Highlights Alumis’s (ALMS) Potential After Envudeucitinib Hits All Phase 3 Endpoints in Psoriasis Trials - Insider Monkey
Alumis Inc. (NASDAQ:ALMS) Short Interest Up 93.1% in January - MarketBeat
Alumis stock hits all-time high at 27.28 USD By Investing.com - Investing.com Australia
Alumis Inc. (ALMS) Stock Analysis: A Biotech Contender With A 34.43% Potential Upside - DirectorsTalk Interviews
10 New Stocks on the Rise - Insider Monkey
Alumis (NASDAQ:ALMS) Hits New 12-Month HighStill a Buy? - MarketBeat
Alumis stock hits all-time high at 27.28 USD - Investing.com
Alumis (NASDAQ:ALMS) Trading Up 6.4%Should You Buy? - MarketBeat
Stock Market Today, Jan. 6: Alumis Shares Surge on Positive Phase 3 Psoriasis Data for Envudeucitinib - AOL.com
Alumis (NASDAQ:ALMS) Coverage Initiated by Analysts at Chardan Capital - MarketBeat
Alumis stock reaches all-time high at 25.25 USD By Investing.com - Investing.com Australia
This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Chardan Capital initiates coverage on Alumis stock with Buy rating - Investing.com
Chardan Capital initiates coverage on Alumis stock with Buy rating By Investing.com - Investing.com Nigeria
Profit Recap: Is now the right time to enter ASTCJuly 2025 WrapUp & Technical Confirmation Alerts - baoquankhu1.vn
Trading Recap: Is Alumis Inc gaining market shareJuly 2025 Market Mood & Growth Focused Entry Point Reports - baoquankhu1.vn
Aug Reactions: What is the long term forecast for XPLR Infrastructure LP Limited Partnership stock - baoquankhu1.vn
Alumis stock reaches all-time high at 25.25 USD - Investing.com
Aug Weekly: What’s Enterprise Products Partners L.P. Limited Partnership’s historical returnMarket Activity Report & Daily Risk Controlled Trade Plans - baoquankhu1.vn
Huge Insider Buying Now at This Insurance Giant and 2 Biotechs - 24/7 Wall St.
Alumis (ALMS) Is Up 22.0% After Phase 3 Psoriasis Win And $300 Million Equity Raise - Yahoo Finance
HC Wainwright & Co. hikes Alumis Inc. (ALMS)’s price target to $40 from $20, reiterates buy rating - MSN
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):